| Name | Title | Contact Details |
|---|
Bio-Path is a biotechnology company developing targeted therapies for acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and other challenging cancers. The company`s lead product candidate, prexigebersen (Liposomal Grb2 Antisense), formerly BP1001, is currently being assessed in a Phase 2 clinical study in 54 people with previously untreated AML who are not eligible for or who have decided to forego intensive induction therapy because of their age or fragile health.
Hazel Technologies develops products that extend the shelf life of produce. Our customers include some of the largest produce growers in the world.
OpGen, Inc. is a leading innovator in rapid, accurate genomic and DNA analysis systems and services.
The most innovative, patient and provider focused preventative diagnostic laboratory in the industry
Corbus Pharmaceuticals Holdings, Inc.is a Phase 3 clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases.